Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-9908 in Non-resectable Hepatocellular Carcinoma Following TACE
NCT03812874Phase 2Withdrawn
- Sponsor
- TCM Biotech International Corp.
- Start
- Oct 2020
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing PTX-9908 Injection group with Placebo/Vehicle group (2 arms). Primary endpoints: Adverse Events at 16 weeks and Dose Limiting Toxicities at 6 weeks. Planned start Oct 2020; status: withdrawn.
02
Drugs
CTCE-9908
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03812874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812874.